According to previous reports, activation of RAF-MEK-ERK and PI3K-AKT signaling pathways play important roles in the resistance to EGFR-TKIs of NSCLC, such as gefitinib and erlotinib4, 5. Here, MAP2K7 is linked to non-small cell lung carcinoma.